These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 30520987)

  • 1. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.
    Fishman JA; Hogan JI; Maus MV
    Clin Infect Dis; 2019 Aug; 69(6):909-920. PubMed ID: 30520987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactions Related to CAR-T Cell Therapy.
    Miao L; Zhang Z; Ren Z; Li Y
    Front Immunol; 2021; 12():663201. PubMed ID: 33995389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy.
    Liu YH; Zang XY; Wang JC; Huang SS; Xu J; Zhang P
    Biomed Pharmacother; 2019 Dec; 120():109437. PubMed ID: 31590992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-related Adverse Events in Cancer Patients.
    Pallin DJ; Baugh CW; Postow MA; Caterino JM; Erickson TB; Lyman GH
    Acad Emerg Med; 2018 Jul; 25(7):819-827. PubMed ID: 29729100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncologic Emergencies: Immune-Based Cancer Therapies and Complications.
    Long B; Brém E; Koyfman A
    West J Emerg Med; 2020 Apr; 21(3):566-580. PubMed ID: 32421502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurological Immunotoxicity from Cancer Treatment.
    Wesley SF; Haggiagi A; Thakur KT; De Jager PL
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-T cell therapy and infection: a review.
    Bupha-Intr O; Haeusler G; Chee L; Thursky K; Slavin M; Teh B
    Expert Rev Anti Infect Ther; 2021 Jun; 19(6):749-758. PubMed ID: 33249873
    [No Abstract]   [Full Text] [Related]  

  • 10. Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management.
    Kovac MB; Seruga B
    Radiol Oncol; 2024 Jun; 58(2):170-178. PubMed ID: 38613842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.
    Pauken KE; Dougan M; Rose NR; Lichtman AH; Sharpe AH
    Trends Immunol; 2019 Jun; 40(6):511-523. PubMed ID: 31053497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.
    Kroschinsky F; Stölzel F; von Bonin S; Beutel G; Kochanek M; Kiehl M; Schellongowski P;
    Crit Care; 2017 Apr; 21(1):89. PubMed ID: 28407743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nephrotoxicity of new immunotherapies.
    Sury K; Perazella MA
    Expert Rev Clin Pharmacol; 2019 Jun; 12(6):513-521. PubMed ID: 31035801
    [No Abstract]   [Full Text] [Related]  

  • 15. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.
    Perrinjaquet C; Desbaillets N; Hottinger AF
    Curr Opin Neurol; 2019 Jun; 32(3):500-510. PubMed ID: 30893101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of cancer immunotherapy toxicity.
    Kennedy LB; Salama AKS
    CA Cancer J Clin; 2020 Mar; 70(2):86-104. PubMed ID: 31944278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
    Baik AH; Oluwole OO; Johnson DB; Shah N; Salem JE; Tsai KK; Moslehi JJ
    Circ Res; 2021 May; 128(11):1780-1801. PubMed ID: 33934609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential Effect of Immunotherapy Agents on Cognitive Function in Cancer Patients.
    Joly F; Castel H; Tron L; Lange M; Vardy J
    J Natl Cancer Inst; 2020 Feb; 112(2):123-127. PubMed ID: 31504664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical care of chimeric antigen receptor T-cell patients and managing immune-related adverse effects in the ambulatory and hospitalized setting: a review.
    Hays P; Costello C; Asudani D
    Future Oncol; 2019 Dec; 15(36):4235-4246. PubMed ID: 31773980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.